- Library Home /
- Search Collections /
- Open Collections /
- Browse Collections /
- UBC Faculty Research and Publications /
- Consensus guideline for the diagnosis and treatment...
Open Collections
UBC Faculty Research and Publications
Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies Opladen, Thomas; López-Laso, Eduardo; Cortès-Saladelafont, Elisenda; Pearson, Toni S; Sivri, H. S; Yildiz, Yilmaz; Assmann, Birgit; Kurian, Manju A; Leuzzi, Vincenzo; Heales, Simon; Pope, Simon; Porta, Francesco; García-Cazorla, Angeles; Honzík, Tomáš; Pons, Roser; Regal, Luc; Goez, Helly; Artuch, Rafael; Hoffmann, Georg F; Horvath, Gabriella; Thöny, Beat; Scholl-Bürgi, Sabine; Burlina, Alberto; Verbeek, Marcel M; Mastrangelo, Mario; Friedman, Jennifer; Wassenberg, Tessa; Jeltsch, Kathrin; Kulhánek, Jan; Kuseyri Hübschmann, Oya
Abstract
Background: Tetrahydrobiopterin (BH₄) deficiencies comprise a group of six rare neurometabolic disorders characterized by insufficient synthesis of the monoamine neurotransmitters dopamine and serotonin due to a disturbance of BH₄ biosynthesis or recycling. Hyperphenylalaninemia (HPA) is the first diagnostic hallmark for most BH₄ deficiencies, apart from autosomal dominant guanosine triphosphate cyclohydrolase I deficiency and sepiapterin reductase deficiency. Early supplementation of neurotransmitter precursors and where appropriate, treatment of HPA results in significant improvement of motor and cognitive function. Management approaches differ across the world and therefore these guidelines have been developed aiming to harmonize and optimize patient care. Representatives of the International Working Group on Neurotransmitter related Disorders (iNTD) developed the guidelines according to the SIGN (Scottish Intercollegiate Guidelines Network) methodology by evaluating all available evidence for the diagnosis and treatment of BH₄ deficiencies. Conclusion: Although the total body of evidence in the literature was mainly rated as low or very low, these consensus guidelines will help to harmonize clinical practice and to standardize and improve care for BH₄ deficient patients.
Item Metadata
Title |
Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies
|
Creator |
Opladen, Thomas; López-Laso, Eduardo; Cortès-Saladelafont, Elisenda; Pearson, Toni S; Sivri, H. S; Yildiz, Yilmaz; Assmann, Birgit; Kurian, Manju A; Leuzzi, Vincenzo; Heales, Simon; Pope, Simon; Porta, Francesco; García-Cazorla, Angeles; Honzík, Tomáš; Pons, Roser; Regal, Luc; Goez, Helly; Artuch, Rafael; Hoffmann, Georg F; Horvath, Gabriella; Thöny, Beat; Scholl-Bürgi, Sabine; Burlina, Alberto; Verbeek, Marcel M; Mastrangelo, Mario; Friedman, Jennifer; Wassenberg, Tessa; Jeltsch, Kathrin; Kulhánek, Jan; Kuseyri Hübschmann, Oya
|
Contributor | |
Publisher |
BioMed Central
|
Date Issued |
2020-05-26
|
Description |
Background:
Tetrahydrobiopterin (BH₄) deficiencies comprise a group of six rare neurometabolic disorders characterized by insufficient synthesis of the monoamine neurotransmitters dopamine and serotonin due to a disturbance of BH₄ biosynthesis or recycling. Hyperphenylalaninemia (HPA) is the first diagnostic hallmark for most BH₄ deficiencies, apart from autosomal dominant guanosine triphosphate cyclohydrolase I deficiency and sepiapterin reductase deficiency. Early supplementation of neurotransmitter precursors and where appropriate, treatment of HPA results in significant improvement of motor and cognitive function. Management approaches differ across the world and therefore these guidelines have been developed aiming to harmonize and optimize patient care. Representatives of the International Working Group on Neurotransmitter related Disorders (iNTD) developed the guidelines according to the SIGN (Scottish Intercollegiate Guidelines Network) methodology by evaluating all available evidence for the diagnosis and treatment of BH₄ deficiencies.
Conclusion:
Although the total body of evidence in the literature was mainly rated as low or very low, these consensus guidelines will help to harmonize clinical practice and to standardize and improve care for BH₄ deficient patients.
|
Subject |
Tetrahydrobiopterin deficiency; BH4; Neurotransmitter; Guanosine triphosphate cyclohydrolase deficiency; 6-pyruvoyltetrahydropterin synthase deficiency; Sepiapterin reductase deficiency, pterin-4-alpha-carbinolamine dehydratase deficiency; Dihydropteridine reductase deficiency; Hyperphenylalaninemia; iNTD; Consensus guidelines; SIGN
|
Genre | |
Type | |
Language |
eng
|
Date Available |
2020-05-28
|
Provider |
Vancouver : University of British Columbia Library
|
Rights |
Attribution 4.0 International (CC BY 4.0)
|
DOI |
10.14288/1.0391050
|
URI | |
Affiliation | |
Citation |
Orphanet Journal of Rare Diseases. 2020 May 26;15(1):126
|
Publisher DOI |
10.1186/s13023-020-01379-8
|
Peer Review Status |
Reviewed
|
Scholarly Level |
Faculty
|
Copyright Holder |
The Author(s)
|
Rights URI | |
Aggregated Source Repository |
DSpace
|
Item Media
Item Citations and Data
Rights
Attribution 4.0 International (CC BY 4.0)